CRISM Therapeutics (LON:CRTX) Releases Quarterly Earnings Results

CRISM Therapeutics (LON:CRTX) posted its quarterly earnings data on Friday. The company reported GBX (0.05) earnings per share for the quarter, Digital Look Earnings reports.

CRISM Therapeutics Stock Performance

Shares of CRTX stock traded down GBX 0.50 on Friday, hitting GBX 9.50. The company had a trading volume of 258,541 shares, compared to its average volume of 291,726. CRISM Therapeutics has a twelve month low of GBX 8 and a twelve month high of GBX 23. The firm has a market cap of £5.15 million, a P/E ratio of -2.16 and a beta of 0.58. The stock’s 50-day moving average is GBX 11.50 and its two-hundred day moving average is GBX 11.67.

About CRISM Therapeutics

CRISM Therapeutics Corporation is clinical stage company, having developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM’s lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin.